Novartis Broadens VISION On Radioligands
Firm Prepares For Expansion Into Prostate Cancer
Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge.
You may also be interested in...
"We have big plans," oncology president Susanne Schaffert said in an interview about launching Pluvicto, its new radioligand therapy for prostate cancer.
Despite the sector's woes, strong companies that generate strong patient data based on solid science have a promising future, Precirix CEO Ruth Devenyns tells Scrip.
Scrip spoke with global development head and chief medical officer John Tsai about the factors Novartis considers when it decides which R&D programs to advance, including externally sourced assets.